Login Register Cart 0
Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Cardiovascular Disease in Patients with Diabetes: A Comparison of Professional Society Guidelines

Author(s): Ilton M. Cubero Salazar, Martin Tibuakuu, Roger S. Blumenthal and Sudipa Sarkar*

Volume 18, Issue 4, 2022

Published on: 06 January, 2022

Article ID: e200821195733 Pages: 7

DOI: 10.2174/1573399817666210820105514

Price: $65

Abstract

In this review, we compare major points given in the 2021 American Diabetes Association and the 2020 American Association of Clinical Endocrinologists/American College of Endocrinology guidelines, in particular, the assessment and management of cardiovascular risk in patients with diabetes with a focus on dyslipidemia, blood pressure, and pharmacotherapy in diabetes.

Keywords: Diabetes, cardiovascular disease, hypertension, atherosclerosis, hyperlipidemia.

[1]
Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the american heart association. Circulation 2019; 139(10): e56-e528.
[http://dx.doi.org/10.1161/CIR.0000000000000659] [PMID: 30700139]
[2]
Garber AJ, Handelsman Y, Grunberger G, et al. COnsensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract 2020; 26(1): 107-39.
[http://dx.doi.org/10.4158/CS-2019-0472] [PMID: 32022600]
[3]
American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2021. Diabetes Care 2021; 44(Suppl. 1): S125-50.
[http://dx.doi.org/10.2337/dc21-S010] [PMID: 33298421]
[4]
American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care 2021; 44(Suppl. 1): S111-24.
[http://dx.doi.org/10.2337/dc21-S009] [PMID: 33298420]
[5]
The atherosclerosis risk in communities (ARIC) study: design and objectives. The ARIC investigators. Am J Epidemiol 1989; 129(4): 687-702.
[http://dx.doi.org/10.1093/oxfordjournals.aje.a115184] [PMID: 2646917]
[6]
Fried LP, Borhani NO, Enright P, et al. The cardiovascular health study: design and rationale. Ann Epidemiol 1991; 1(3): 263-76.
[http://dx.doi.org/10.1016/1047-2797(91)90005-W] [PMID: 1669507]
[7]
Friedman GD, Cutter GR, Donahue RP, et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol 1988; 41(11): 1105-16.
[http://dx.doi.org/10.1016/0895-4356(88)90080-7] [PMID: 3204420]
[8]
Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129(25)(Suppl. 2): S49-73.
[http://dx.doi.org/10.1161/01.cir.0000437741.48606.98] [PMID: 24222018]
[9]
Arnett DK, Khera A, Blumenthal RS. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: part 1, lifestyle and behavioral factors. JAMA Cardiol 2019; 4(10): 1043-4.
[http://dx.doi.org/10.1001/jamacardio.2019.2604] [PMID: 31365022]
[10]
Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012; 307(12): 1302-9.
[http://dx.doi.org/10.1001/jama.2012.366] [PMID: 22453571]
[11]
Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372(25): 2387-97.
[http://dx.doi.org/10.1056/NEJMoa1410489] [PMID: 26039521]
[12]
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376(18): 1713-22.
[http://dx.doi.org/10.1056/NEJMoa1615664] [PMID: 28304224]
[13]
Giugliano RP, Cannon CP, Blazing MA, et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from improve-it (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation 2018; 137(15): 1571-82.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.117.030950] [PMID: 29263150]
[14]
Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol 2017; 5(12): 941-50.
[http://dx.doi.org/10.1016/S2213-8587(17)30313-3] [PMID: 28927706]
[15]
Amarenco P, Kim JS, Labreuche J, et al. A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med 2020; 382(1): 9.
[http://dx.doi.org/10.1056/NEJMoa1910355] [PMID: 31738483]
[16]
Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362(17): 1575-85.
[http://dx.doi.org/10.1056/NEJMoa1001286] [PMID: 20228401]
[17]
Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373(22): 2103-16.
[http://dx.doi.org/10.1056/NEJMoa1511939] [PMID: 26551272]
[18]
Bress AP, King JB, Kreider KE, et al. Effect of intensive versus standard blood pressure treatment according to baseline prediabetes status: a post hoc analysis of a randomized trial. Diabetes Care 2017; 40(10): 1401-8.
[http://dx.doi.org/10.2337/dc17-0885] [PMID: 28793997]
[19]
Margolis KL, O’Connor PJ, Morgan TM, et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care 2014; 37(6): 1721-8.
[http://dx.doi.org/10.2337/dc13-2334] [PMID: 24595629]
[20]
Beddhu S, Chertow GM, Greene T, et al. Effects of intensive systolic blood pressure lowering on cardiovascular events and mortality in patients with type 2 diabetes mellitus on standard glycemic control and in those without diabetes mellitus: reconciling results from accord bp and sprint. J Am Heart Assoc 2018; 7(18): e009326.
[http://dx.doi.org/10.1161/JAHA.118.009326] [PMID: 30371182]
[21]
American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2021. Diabetes Care 2021; 44(Suppl. 1): S73-84.
[http://dx.doi.org/10.2337/dc21-S006] [PMID: 33298417]
[22]
Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019; 7(10): 776-85.
[http://dx.doi.org/10.1016/S2213-8587(19)30249-9] [PMID: 31422062]
[23]
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375(19): 1834-44.
[http://dx.doi.org/10.1056/NEJMoa1607141] [PMID: 27633186]
[24]
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375(4): 311-22.
[http://dx.doi.org/10.1056/NEJMoa1603827] [PMID: 27295427]
[25]
Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394(10193): 121-30.
[http://dx.doi.org/10.1016/S0140-6736(19)31149-3] [PMID: 31189511]
[26]
Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018; 392(10157): 1519-29.
[http://dx.doi.org/10.1016/S0140-6736(18)32261-X] [PMID: 30291013]
[27]
Arnott C, Li Q, Kang A, et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc 2020; 9(3): e014908.
[http://dx.doi.org/10.1161/JAHA.119.014908] [PMID: 31992158]
[28]
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373(22): 2117-28.
[http://dx.doi.org/10.1056/NEJMoa1504720] [PMID: 26378978]
[29]
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377(7): 644-57.
[http://dx.doi.org/10.1056/NEJMoa1611925] [PMID: 28605608]
[30]
Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380(4): 347-57.
[http://dx.doi.org/10.1056/NEJMoa1812389] [PMID: 30415602]
[31]
Heyward J, Mansour O, Olson L, Singh S, Alexander GC. Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis. PLoS One 2020; 15(6): e0234065.
[http://dx.doi.org/10.1371/journal.pone.0234065] [PMID: 32502190]
[32]
Lin C, Zhu X, Cai X, et al. SGLT2 inhibitors and lower limb complications: An updated meta-analysis. Cardiovasc Diabetol 2021; 20(1): 91.
[http://dx.doi.org/10.1186/s12933-021-01276-9] [PMID: 33910574]

Rights & Permissions Print Cite
Article Metrics
21
1
© 2024 Bentham Science Publishers | Privacy Policy